The FDA is asking for more details about Heplisav-B's postmarketing surveillance plan, but Dynavax executives and analysts said they remain confident.
For three of the world’s top four vaccine companies, sales growth churned along in the second quarter as other areas struggled.
At Dynavax’s third try, an FDA panel favored hepatitis B candidate Heplisav-B's safety profile by a vote of 12 to 1.
While GSK is still expected to top the vaccine industry in 2022, rankings for other players have shifted in Evaluate's new World Preview.
Six senators are railing on Sanofi for its role in a Zika pricing dustup that’s gained considerable attention since last year.
The EU's highest court ruled that EU national courts don't need scientific proof to consider a vaccine as defect.
Merck & Co. may not be number one with a bullet in vaccines, but CEO Ken Frazier says the unit shouldn't be underestimated.
Bexsero has been helping drive revenue growth for GSK, but now, with an EU approval, Pfizer’s Trumenba is set to challenge it in that lucrative market.
A Sanofi executive has explained the rationale behind the company’s Zika vaccine development plan and is issuing a defense against claims his company is out to…
GSK's Cervarix may have been the first HPV shot approved in mainland China, but Merck's Gardasil now has an opening to gain the lead.